Abstract:
Novel, genetically modified mammalian cell lines are described, which can produce glycoconjugates the oligosaccharide portions of which are more similar to the human one than those of the same glycoconjugates produced by cells which have not been genetically modified. The lines in question can be used for the production of recombinant glycoconjugates which are of therapeutic interest, in particular for the production of glycoproteins for use in human therapy, since the glycoconjugates produced in these modified lines have a lower immunogenic potential for man than corresponding glycoconjugates produced in cells which have not been genetically modified.
Abstract:
An machine (1) for multiple beverage dispensing, particularly for coffee and/or still or carbonated water and/or hot and/or chilled beverages, comprising a container of water (2), which can be associated with a box-like support (3), to which a first tank (9) for water at room temperature and a contiguous second refrigeration tank (10) are connected, respectively to a first duct (11) and to a second duct (12). The second duct (12) is connected to means for carbonating the water and downstream of the first duct (11) for the selective dispensing of water at room temperature or chilled water. The first duct (11) is further connected, by way of a third duct (22), to means for the selective dispensing of hot beverages or coffee. The machine (1) allows to combine in a single solution several functions that are currently present in separate devices, achieving high functional versatility, space optimization and reduced transport and packaging costs.
Abstract:
The subject of the present invention is the construction of multicistronic eukaryotic plasmid expression vectors in which it is possible to express from two to four genes simultaneously and which are characterized by differently regulated bicistronic transcription units. The distinctive characteristic of these vectors is the presence of a CAP-independent translation initiation mechanism which is based on the ability of an IRES (internal ribosomal entry site) sequence to translate two proteins under the control of a single promoter. This family of multicistronic vectors can advantageously be used in various biotechnological applications in whcih the simultaneous expression of two or more genes is necessary, such as gene transfer protocols, DNA-immunization, or for the expression of different molecules in the same cell.
Abstract:
Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activit y.
Abstract:
There are disclosed chemically active poly(ethylene glycols) and other hydrophilic polymers that are suitable for coupling to pharmaceutically or diagnostically active agents such as peptides, oligonucleotides, proteins or non- peptide molecules. The compounds are represented by the formula Poly-(X-NH-CO-A) n wherein: Poly is a hydrophilic polymer having a molecular weight of from about 300 to 100000 Daltons; A together with -NH-CO- forms a reactive group; X is a spacer moiety or a bond; n is an integer comprised between 1 and 50. The active agents of interest which may be conjugated to the disclosed compounds may be selected from hemoglobin, insulin, urokinase, alpha- interferon, G-CSF, hGH, asparaginase, adenosine deaminase, superoxide dismutase and catalase.
Abstract translation:公开了化学活性聚(乙二醇)和其它亲水性聚合物,其适于与药学或诊断活性剂如肽,寡核苷酸,蛋白质或非肽分子偶联。 所述化合物由下式表示:Poly-(X-NH-CO-A)n N n其中:Poly是分子量为约300至100000道尔顿的亲水性聚合物; A与-NH-CO-一起形成反应性基团; X是间隔部分或键; 可以与所公开的化合物缀合的感兴趣的活性剂可以选自血红蛋白,胰岛素,尿激酶,α-干扰素,G-CSF,hGH,天冬酰胺酶,腺苷脱氨酶,超氧化物歧化酶 和过氧化氢酶。
Abstract:
N(hetero)-aryl-N(hetero)-tetralinalkyl piperazine having serotoninergic, dopaminergic and adrenergic activity, the processes for their preparation and relative therapeutic compositions for the treatment of anxiety generated by depression, for the treatment of schizophrenia, cerebral ischemia, opium like and psycho stimulant substances abuse syndromes consciousness disorders such as senile dementia, vigilance and memory disorders. Parkinson's and Alzheimer's diseases and for the treatment of arterial hypertension.
Abstract:
The present invention is related to glucagon-like peptide- 1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.
Abstract:
The use of wet silica based polymers obtained by the sol-gel technology for the entrapment and sustained release of macromolecular bioactive compounds and, more specifically, proteins with pharmaceutical applications, is disclosed. The wet-gel formulations are obtained by a method which comprises mixing an alkoxysilane solution, a gelling catalyst and a buffered water solution of a biologically active principle and subsequently casting the thus-obtained mixture into suitable containers without previous or subsequent partial or complete removal of the water solvent; the containers are then sealed after casting in order to preserve the wet state of the gel. The wet-gel formulations may then be used for the manufacture of a ready-to-use injectable solution by mixing the silica wet-gel formulation with water or with a physiological water solution.
Abstract:
The present invention relates to the expression and secretion in Saccharomyces cerevisiae of readily purifiable soluble variants of the Kex1 endopeptidase of Kluyveromyces lactis in vitro processing of recombinant proteins usable in industrial applications. The soluble Kex1 endoproteases described here are free from the transmembrane domain of the native enzyme; the deletion of the transmembrane domain is achieved by removing at least 57 amino acid residues from the C-terminal.
Abstract:
Strains of genetically modified prokaryotic micro-organisms capable of expressing polypeptides having the enzyme activity of the enzymes uridine phosphorylase (UdP) and purine nucleoside phosphorylase (PNP) are described; the strains in question can be used, both in the form of whole cells and in the form of crude or purified extracts, to catalyse transglycosylation reactions between a donor nucleoside and an acceptor base with particularly high yields. The associated plasmid vectors are also described.